Replies to post #216883 on Innovation Pharmaceuticals Inc (IPIX)

[Scottwny]

Thanks for your input. Can P53 activation occur by chance? My concern is that the study only enrolled a handful of people, so any data collected doesn't hold very significant value to me (unless of course the P53 activation could have only occurred from introducing K to the body). As I stated before, some of this science stuff is over my head.

[biodoc]

Great post, Farrell90. Thank you.

Excellent summary of important Kevetrin history. Activating targeted biomarkers in tumor tissue was really key to the study. It's a great study to advance our understanding of Kevetrin (and increase its value to BP) but it didn't present a compelling argument for patient enrollment. Now it's time to turn it over to BP or to an aggressive well-funded smaller company that can really run with it.

Importantly, these data are the first to directly support, in ovarian cancer patient tumors, Kevetrin’s ability to affect p53 and associated molecular pathways—a central gene signaling network involved in regulating cell growth and the cell cycle, helping to prevent cancer.

These new data reinforce prior clinical data, from the earlier concluded Phase 1 study of Kevetrin in advanced solid tumors (see NCT01664000), in which observations of p21 expression in peripheral blood monocytes supported p53 involvement in Kevetrin’s mechanism of action.

12/27/2017 PR

I agree that oral Kevetrin will soon be available for human testing. It's a big step that takes longer than most realize. We're getting close. From March 3, 2017:

Cellceutix has initiated a series of GLP (Good Laboratory Practice) studies to assess the safety of Kevetrin given orally. Considering that Kevetrin is a non-cytotoxic drug, our intent, with FDA permission, is to next proceed with a Phase 1 clinical trial in healthy volunteers using the oral route. These studies are being conducted by approved vendors and include: photosafety testing, pharmacokinetics, in vivo metabolism, metabolic stability, protein binding, and genetic and physiological toxicology reports.

As far as value to Big Pharma, it's compelling.
biodoc